Anzeige
Mehr »
Login
Donnerstag, 17.06.2021 Börsentäglich über 12.000 News von 662 internationalen Medien
InnoCan Pharma deklassiert die Konkurrenz! - Kursexplosion?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14Z67 ISIN: IE00BYZ5XL97 Ticker-Symbol: 69BN 
Tradegate
15.06.21
15:25 Uhr
2,360 Euro
-0,020
-0,84 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
STRONGBRIDGE BIOPHARMA PLC Chart 1 Jahr
5-Tage-Chart
STRONGBRIDGE BIOPHARMA PLC 5-Tage-Chart
RealtimeGeldBriefZeit
2,3602,46018:59
2,3602,44019:04
Dow Jones News
215 Leser
Artikel bewerten:
(1)

Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc

DJ Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc

The Vanguard Group, Inc. ( IRSH) 
Form 8.3 - The Vanguard Group, Inc.: Strongbridge Biopharma plc 
11-Jun-2021 / 13:56 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Ap19 
 
FORM 8.3 
 
IRISH TAKEOVER PANEL 
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 
 
DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 
 
1. KEY INFORMATION 
 
Name of person dealing (Note 1)                         The Vanguard Group, Inc. 
Company dealt in                                 Strongbridge Biopharma plc 
Class of relevant security to which the dealings being disclosed relate (Note 2) USD0.01 Ordinary Shares 
Date of dealing                                 09 June 2021 

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long      Short 
                       Numbers  (%)  Numbers (%) 
(1) Relevant securities           2,315,587 3.42% 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total                    2,315,587 3.42% 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:         Long    Short 
                       Numbers (%) Numbers (%) 
(1) Relevant securities 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total 

Ap20

1. Dealings (Note 4)

(a) Purchases and sales

Purchase/sale Number of relevant securities Price per unit (Note 5) 
Sale     490              2.86 USD 
Purchase   16               2.86 USD 

(b) Derivatives transactions (other than options transactions)

Product name, Nature of transaction Number of relevant securities Price per unit 
e.g. CFD    (Note 6)       (Note 7)           (Note 5) 
Not Applicable 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, Writing, selling,  Number of securities to        Type, e.g.        Option money paid/ 
       purchasing, varying which the option relates   Exercise American,     Expiry received per unit 
e.g. call   etc.         (Note 7)           price  European etc.   date  (Note 5) 
option 
Not 
Applicable 

(ii) Exercising

Product name,             Exercise price per unit (Note 5) 
         Number of securities 
e.g. call option 
Not Applicable 

(e) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction     Price per unit 
           Details 
(Note 8)           (if applicable) (Note 5) 
Not Applicable 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating 
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting 
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is 
referenced. If none, this should be stated. 
 
 
 
 

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure                        11 June 2021 
Contact name                           Shawn Acker 
Telephone number                         001-610-669-8989 
If a connected EFM, name of offeree/offeror with which connected 
If a connected EFM, state nature of connection (Note 10) ----------------------------------------------------------------------------------------------------------------------- 
Category Code: RET - Strongbridge Biopharma plc 
TIDM:     IRSH 
LEI Code:   5493002789CX3L0CJP65 
Sequence No.: 110886 
EQS News ID:  1207187 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1207187&application_name=news 
 

(END) Dow Jones Newswires

June 11, 2021 08:57 ET (12:57 GMT)

STRONGBRIDGE BIOPHARMA-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 Dow Jones News
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.